Clinical Overview
Mesoridazine was a phenothiazine antipsychotic that was indicated specifically for treatment-resistant schizophrenia in patients who failed to respond to other antipsychotic agents. Important Note: This medication was withdrawn from the US market in 2004 due to serious cardiac safety concerns, particularly QT prolongation and life-threatening arrhythmias.
Historical Clinical Applications
Mesoridazine was reserved for schizophrenic patients who were unresponsive to or could not tolerate other antipsychotic medications. Its use was limited due to significant cardiovascular risks that ultimately led to its market withdrawal.
Mechanism and Safety Concerns
As a phenothiazine, mesoridazine blocked dopamine receptors, but also had significant effects on cardiac ion channels, leading to dangerous QT interval prolongation and increased risk of sudden cardiac death.
Current Status
This medication is no longer available in the United States and should not be prescribed. Patients previously on mesoridazine should be transitioned to safer alternative antipsychotics.
Prescribing Information
Market Status
- DISCONTINUED: Withdrawn from US market in 2004
- Reason: Unacceptable cardiac safety profile
- Current Recommendation: Use alternative antipsychotics
Historical Indications
- Treatment-resistant schizophrenia (last-line therapy only)
- Patients unresponsive to other antipsychotics
Contraindications
- All patients – medication discontinued
- Previously contraindicated in: cardiac arrhythmias, QT prolongation, severe CNS depression
Warnings & Precautions
- BLACK BOX WARNING: Medication withdrawn due to life-threatening cardiac effects
- QT prolongation leading to torsades de pointes
- Sudden cardiac death risk
- No longer considered safe for clinical use
Alternative Treatments
Recommended Alternatives for Treatment-Resistant Schizophrenia:
- Clozapine: Gold standard for treatment-resistant cases
- Second-generation antipsychotics: Olanzapine, risperidone, quetiapine
- Long-acting injectables: For compliance issues
Transition Considerations
- Patients previously on mesoridazine require immediate alternative therapy
- Gradual cross-titration to avoid withdrawal symptoms
- Cardiac monitoring during transition period
Special Populations
- All Populations: Medication no longer available
- Historical Use: Was contraindicated in elderly due to increased mortality risk
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
